Logo

Samuel Riccitelli, David Cohen

Nov 14, 2017

Precipio has appointed Samuel Riccitelli as chairman, replacing Robert Patzig who resigned after seven years on the board of Transgenomic, which recently merged with Precipio. Also, David Cohen was elected as a new director at Precipio to fill an existing vacancy. 

Riccitelli has been on Precipio's board since June. From October 2012 through February 2017, he was president and CEO of Signal Genetics, where he also was a director. Before that, he was executive vice president and COO of Genoptix.

Cohen is COO and co-owner of Standard Oil of Connecticut, and has founded several ventures, including My Gene Counsel, a cancer bioinformatics company.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.